Literature DB >> 16868703

Serum markers of bone turnover in dialyzed patients separated according to age.

Alicja E Grzegorzewska1, Monika Młot.   

Abstract

BACKGROUND: Bone metabolism changes with aging in healthy population. Our aim was to determine serum markers of bone turnover in dialysis patients separated according to age.
METHODS: Peritoneal dialysis (PD) or hemodialysis (HD) patients were divided into two groups. Group I (n = 30) consisted of patients older than 65 years. Patients at the age less or equal 65 years were included in group II (n = 37). In all patients we determined serum concentration of intact parathyroid hormone (iPTH), cyclase activating parathyroid hormone (CAP), osteoprotegrin (OPG) and osteoprotegrin ligand (OPGL). Cyclase inactive parathyroid hormone (CIP) was calculated. Healthy volunteers (n = 13) at the age of 42.1 years (range 23.5-70.9 years) served as controls.
RESULTS: When results of dialysis patients were adjusted to gender, dialysis modality and duration, group I revealed significantly lower iPTH (113.0, 10.3-606.3 pg/ml), CAP (70.0, 6.5-442.6 pg/ml) and CIP (53.3, 3.3-214.4 pg/ml) than group II (310.6, 13.7-1266.9 pg/ml for iPTH; 205.0, 9.3-887.9 pg/ml for CAP; 76.0, 2.4-399.0 pg/ml for CIP), but this group showed significantly higher serum OPG (7.39, 1.52-15.84 pg/ml) than group II (5.45, 0.95-16.47 pg/ml) and controls (2.17, 1.05-3.95 pg/ml). Only patients of group II showed significantly higher iPTH, CAP and CIP than controls (34.9, 18.9-76.9 pg/ml; 24.3, 11.2-42.6 pg/ml, 12.0, 1.0-34.2 pg/ml, respectively for iPTH, CAP and CIP).
CONCLUSION: Our results suggest that age over 65 years is a risk factor for low bone turnover in dialyzed patients. An increase in serum OPG probably reflects a paracrine mechanism of bone cells to compensate for age dependent bone loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868703     DOI: 10.1007/s11255-006-0079-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  28 in total

1.  Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Authors:  Astrid Fahrleitner-Pammer; Harald Dobnig; Claudia Piswanger-Soelkner; Christine Bonelli; Hans-Peter Dimai; Georg Leb; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

2.  Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.

Authors:  Lia Pulsatelli; Paolo Dolzani; Tania Silvestri; Paolo Caraceni; Andrea Facchini; Giovanni Ravaglia; Carlo Salvarani; Riccardo Melicòni; Erminia Mariani
Journal:  Biogerontology       Date:  2004       Impact factor: 4.277

3.  The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.

Authors:  Ki Won Oh; Eun Jung Rhee; Won Young Lee; San Woo Kim; Eun Sook Oh; Ki Hyun Baek; Moo Il Kang; Moon Gi Choi; Hyung Joon Yoo; Sung Woo Park
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

4.  Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.

Authors:  T Murakami; M Yamamoto; K Ono; M Nishikawa; N Nagata; K Motoyoshi; T Akatsu
Journal:  Biochem Biophys Res Commun       Date:  1998-11-27       Impact factor: 3.575

5.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.

Authors:  L C Hofbauer; C R Dunstan; T C Spelsberg; B L Riggs; S Khosla
Journal:  Biochem Biophys Res Commun       Date:  1998-09-29       Impact factor: 3.575

6.  Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population.

Authors:  Svetlana Trofimov; I Pantsulaia; Ia Pantsulaia; Eugene Kobyliansky; Gregory Livshits
Journal:  Eur J Endocrinol       Date:  2004-03       Impact factor: 6.664

7.  Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells.

Authors:  H Brändström; K B Jonsson; C Ohlsson; O Vidal; S Ljunghall; O Ljunggren
Journal:  Biochem Biophys Res Commun       Date:  1998-06-18       Impact factor: 3.575

8.  TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption.

Authors:  B S Kwon; S Wang; N Udagawa; V Haridas; Z H Lee; K K Kim; K O Oh; J Greene; Y Li; J Su; R Gentz; B B Aggarwal; J Ni
Journal:  FASEB J       Date:  1998-07       Impact factor: 5.191

9.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Authors:  T Akatsu; T Murakami; M Nishikawa; K Ono; N Shinomiya; E Tsuda; S Mochizuki; K Yamaguchi; M Kinosaki; K Higashio; M Yamamoto; K Motoyoshi; N Nagata
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

10.  Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.

Authors:  D Grigorie; Elena Neacşu; Mirela Marinescu; Oana Popa
Journal:  Rom J Intern Med       Date:  2003
View more
  1 in total

1.  Changes of serum bone markers in CAPD and hemodialysis patients.

Authors:  D Yonova; P Dukova
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.